Inclusion Criteria:  Voluntary participation and written informed consent; Age: 18-75 years old;ECOG PS：0-1；The expected survival is more than 6 months; No gender limitation; Histologically confirmed hepatocellular carcinoma; Meet resectable surgical criteria; Child-Pugh:A or B; According to RECIST 1.1, there is at least one evaluable lesion that has not been treated;  Exclusion Criteria:  Fibrolamellar HCC, sarcomatoid HCC, or mixed bile duct cell-HCC is known to exis; Preoperative systemic treatment including chemotherapy, targeted therapy and immunotherapy;Preoperative local treatment including radiotherapy, interventional therapy and ablative therapy; No radical resection could be performed after adequate imaging evaluation; Present or present with other malignant tumors within 3 years.Two conditions were eligible for inclusion: 5 consecutive years of disease-free survival (DFS) for other malignancies treated with a single operation;Cured carcinoma in situ of the cervix, non-melanoma skin cancer, and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basement membrane)]; 5 . There are many factors that affect oral medications (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);  6. Hepatitis B combined with hepatitis C; 7. Patients with portal hypertension have high bleeding risk considered by the researcher, or gastroscopy or gastroscopy confirmed red signs, or gastroscopy found active ulcers with high bleeding risk;